CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

References

• Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11:855–73. doi:10.1517/14712598.2011.573476. PMID:21463133.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25. doi:10.1126/scitranslmed.3008226. PMID:24553386.
   PubMed Web of Science ®Google Scholar
• Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4:e1027469. doi:10.1080/2162402X.2015.1027469. PMID:26451310.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73. doi:10.1126/scitranslmed.3002842. PMID:21832238.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099–102. doi:10.1182/blood-2010-04-281931. PMID:20668228.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–9. doi:10.1200/JCO.2014.56.2025. PMID:25154820.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, Bo J, Fan H, Zhang Y, Zhang YJ, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014;155:160–75. doi:10.1016/j.clim.2014.10.002. PMID:25444722.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang Y, Han W. Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects. J Immunol Res. 2016;2016:3850839. doi:10.1155/2016/3850839. PMID:26998495.
   PubMedGoogle Scholar
• Yu S, Li A, Liu Q, Li T, Yuan X, Han X, Wu K. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10:78. doi:10.1186/s13045-017-0444-9. PMID:28356156.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33:1688–96. doi:10.1200/JCO.2014.58.0225. PMID:25800760.
   PubMed Web of Science ®Google Scholar
• Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, DeMatteo RP, Ayala A, Joseph Espat N, Junghans RP, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64:817–29. doi:10.1007/s00262-015-1692-6. PMID:25850344.
   PubMed Web of Science ®Google Scholar
• Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol: WJG. 2016;22:7645–59. doi:10.3748/wjg.v22.i34.7645..
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. doi:10.1056/NEJMoa0708857. PMID:18650514.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, et al. Randomized, Double-Blind, Phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015;33:4039–47. doi:10.1200/JCO.2015.61.4578. PMID:26351344.
   PubMed Web of Science ®Google Scholar
• Liu B, Song Y, Liu D. Clinical trials of CAR-T cells in China. J Hematol Oncol. 2017;10:166. doi:10.1186/s13045-017-0535-7. PMID:29058636.
   PubMed Web of Science ®Google Scholar
• Schmohl JU, Vallera DA. CD133, Selectively targeting the root of cancer. Toxins. 2016;8:e165. doi:10.3390/toxins8060165. PMID:27240402.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Petrillo M, Bonanno G, Scambia G. Targeting CD133 antigen in cancer. Expert Opin Ther Targets. 2009;13:823–37. doi:10.1517/14728220903005616. PMID:19530986.
   PubMed Web of Science ®Google Scholar
• Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T, Hayashi N. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol. 2010;52:872–9. doi:10.1016/j.jhep.2009.12.030. PMID:20395004.
   PubMed Web of Science ®Google Scholar
• Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953–62. doi:10.1136/gut.2008.176271. PMID:20442200.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11. doi:10.1038/35102167. PMID:11689955.
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–44. doi:10.1158/0008-5472.CAN-06-3126. PMID:16990346.
   PubMedGoogle Scholar
• Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label phase I trial. Clin Cancer Res. 2017;23:1156–66. doi:10.1158/1078-0432.CCR-16-1365. PMID:27582488.
   PubMed Web of Science ®Google Scholar
• Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY, Huang J-h, Yang Q-m, Han W-d. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10:4. doi:10.1186/s13045-016-0378-7. PMID:28057014.
   PubMed Web of Science ®Google Scholar
• Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, Han W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59:468–79. doi:10.1007/s11427-016-5023-8. PMID:26968708.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026. PMID:19097774.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95. doi:10.1182/blood-2014-05-552729. PMID:24876563.
   PubMed Web of Science ®Google Scholar
• ruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. doi:10.1016/S0140-6736(16)32453-9. PMID:27932229.
   PubMed Web of Science ®Google Scholar
• Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A. 1997;94:12425–30. doi:10.1073/pnas.94.23.12425. PMID:9356465.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, et al. Convergence of Acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–95. doi:10.1158/2159-8290.CD-15-1020. PMID:26516065.
   PubMed Web of Science ®Google Scholar
• Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–10. doi:10.1182/blood-2015-08-665547. PMID:26907630.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116. doi:10.1126/scitranslmed.aaf8621. PMID:27605551.
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119–22. doi:10.1097/PPO.0000000000000035. PMID:24667956.
   PubMed Web of Science ®Google Scholar
• Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett. 2014;343:172–8. doi:10.1016/j.canlet.2013.10.004. PMID:24141191.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4. doi:10.1126/science.1076514. PMID:12242449.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels. J Clin Oncol. 2017;35:1803–1813. JCO2016713024.
   Web of Science ®Google Scholar
• Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105:71–7. doi:10.1172/JCI8071. PMID:10619863.
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med. 2005;56:79–101. doi:10.1146/annurev.med.56.090203.104149. PMID:15660503.
   PubMed Web of Science ®Google Scholar
• Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, Tsao HW, Godec J, LaFleur MW, Brown FD, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165–9. doi:10.1126/science.aae0491. PMID:27789799.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21:687–92. doi:10.1158/1078-0432.CCR-14-1860. PMID:25501578.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Science Translational Med. 2016;8:328rv4. doi:10.1126/scitranslmed.aad7118..
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129:1039–41. doi:10.1182/blood-2016-09-738245. PMID:28031179.
   PubMed Web of Science ®Google Scholar